Skip to main content
. Author manuscript; available in PMC: 2022 Mar 18.
Published in final edited form as: Cell Chem Biol. 2021 Mar 18;28(3):271–282. doi: 10.1016/j.chembiol.2021.02.016

Figure 1. Value added benefit of hiPSC-CMs for drug development.

Figure 1

The potential benefit of hiPSC-CMs for drug development includes disease models that bring the human context to discovery and preclinical stages. hIPSC-CM based studies could also be used to discriminate drug-responsive patients with a specific disease that would allow a more precise Phase II clinical trial to be performed. Together, these technologies might improve the efficiency of drug development. In addition, hiPSC-based phenotyping, combined with multi-omics analyses of patient samples, would aid clinicians in prescribing medicines on the basis of mechanism and drug-responsiveness.